Results 121 to 130 of about 31,863 (238)

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations

Blood Advances, 2017
Peter A. Kouides
doaj   +1 more source

Management of bleeds in people living with hemophilia A or B without inhibitors and receiving marstacimab: A plain language summary of publication from the BASIS study. [PDF]

Ther Adv Hematol
Kim HK.
europepmc   +1 more source

Sequential Use of Recombinant Porcine Factor VIII and Early Emicizumab in Acquired Hemophilia A: A Case Series

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder requiring prompt hemostatic control and sustained prevention of rebleeding. Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) controls acute bleeding, while emicizumab provides prophylaxis. Real‐world data on their sequential use are limited.
Yusuke Yamada, Takashi Onaka, Kazunori Imada   +2 more
wiley   +1 more source

[Impact of effective health information acquisition on hemophilia-related health literacy among caregivers of underage hemophilia patients]. [PDF]

Beijing Da Xue Xue Bao Yi Xue Ban
Yuan R, Lin H, Xu Q, Liu X, Shi D, Chang C, Cao J.   +6 more
europepmc   +1 more source

Effectiveness and Safety of Prophylactic Low‐Dose Emicizumab in Young Children With Hemophilia A: A Multicenter Retrospective Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Real‐world data on low‐dose emicizumab in young children with hemophilia A are limited. Methods This multicenter retrospective study included 26 children (median age: 2.2 years) receiving individualized low‐dose emicizumab (2019–2025).
Guichi Zhou, Liya He, Chunyan Wang, Yashuang Deng, Dong Peng, Zhaonan Liu, Sixi Liu, Xiaoying Fu, Ying Wang, Xiaoqin Feng   +9 more
wiley   +1 more source

Occult Hemophilia B and Plastic Surgery: Preventing Bleeding Events. [PDF]

Plast Reconstr Surg Glob Open
Cárdenas-Camarena L, Domínguez-Millán R, López Echaury A.   +2 more
europepmc   +1 more source

[Hemophilia].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2013
openaire   +2 more sources

Variables Affecting Periprocedural Haemostatic Response in Patients With Haemophilia: Real‐World Retrospective Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Patients with haemophilia (PWH) undergoing invasive procedures are at increased risk of periprocedural bleeding, and optimal haemostatic response (HR) depends on patient‐ and procedure‐related factors. We aimed to evaluate variables associated with HR in PWH undergoing invasive procedures.
Jose Antonio Sanchez Salas, Eva Soler Espejo, Faustino García Candel, Vanessa Roldán Schilling   +3 more
wiley   +1 more source

Long-term effect of marstacimab on joints that bleed frequently in people living with severe hemophilia without inhibitors: A plain language summary of publication. [PDF]

Ther Adv Hematol
Kim HK.
europepmc   +1 more source